Quick Answer
Inhibikase Therapeutics, Inc. reported Total Revenue of $0.00 for the year ending 2024.
- Inhibikase Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue from 2023 to 2024.
- This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $270.8 thousand | Q2 2020: $219.6 thousand | Q3 2020: $37.7 thousand | Q1 2021: $1.41 million | Q2 2021: $1.36 million | Q3 2021: $328.5 thousand | Q1 2022: $46.0 thousand | Q2 2022: $6.6 thousand | Q3 2022: $7.3 thousand | Q1 2023: $64.5 thousand | Q2 2023: $116.4 thousand | Q3 2023: $79.6 thousand | Q1 2024: $0.00 | Q2 2024: $0.00 | Q3 2024: $0.00.
- Over the full 5 years of available data (2020 to 2024), Inhibikase Therapeutics, Inc.'s Total Revenue has declined by 100.0%.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $260.5 thousand | Fiscal year 2022: $123.4 thousand | Fiscal year 2021: $3.10 million | Fiscal year 2020: $698.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: